Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.
Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...
Sun Pharma shares rose like the sun in the intraday trade on Tuesday, as the company shares surged by over 2 per cent in the ...
The stock of the country’s largest pharmaceutical company, Sun Pharmaceutical Industries (Sun Pharma), has declined about 15 ...
Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.50. The rise is despite the ...
Sun Pharmaceutical Industries Ltd. closed 15.54% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most ...
Hosted on MSN2d
Sun Pharma Share Price Target Raised to Rs 2,400 – Emkay Research Reiterates ‘BUY’ Rating - DetailsLeading brokerage firm Emkay Research has maintained a bullish stance on Sun Pharma, assigning a ‘BUY’ rating with a price ...
Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback